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Background: The lysosomal storage disorder, mucopolysaccharidosis I (MPS I), commonly manifests with upper
airway obstruction and sleep disordered breathing (SDB). The success of current therapies, including haematopoietic
stem cell transplantation (HSCT) and enzyme replacement therapy (ERT) may be influenced by a number of factors and
monitored using biomarkers of metabolic correction. We describe the pattern of SDB seen in the largest MPS I cohort
described to date and determine therapies and biomarkers influencing the severity of long-term airway disease.
Methods: Therapeutic, clinical and biomarker data, including longitudinal outcome parameters from 150 sleep
oximetry studies were collected in 61 MPS I (44 Hurler, 17 attenuated) patients between 6 months pre to 16 years post-
treatment (median follow-up 22 months). The presence and functional nature of an immune response to ERT was
determined using ELISA and a cellular uptake inhibition assay. Multivariate analysis was performed to determine
significant correlators of airway disease.
Results: The incidence of SDB in our cohort is 68%, while 16% require therapeutic intervention for airway obstruction.
A greater rate of progression (73%) and requirement for intervention is seen amongst ERT patients in contrast to HSCT
treated individuals (24%). Multivariate analysis identifies poorer metabolic clearance, as measured by a rise in the
biomarker urinary dermatan sulphate: chondroitin sulphate (DS:CS) ratio, as a significant correlator of increased
presence and severity of SDB in MPS I patients (p = 0.0017, 0.008). Amongst transplanted Hurler patients, delivered
enzyme (leukocyte iduronidase) at one year is significantly raised in those without SDB (p = 0.004). Cellular uptake
inhibitory antibodies in ERT treated patients correlate with reduced substrate clearance and occurrence of severe SDB
(p = 0.001).
Conclusion: We have identified biochemical and therapeutic factors modifying airway disease across the phenotypic
spectrum in MPS I. Interventions maximising substrate reduction correlate with improved long-term SDB, while
inhibitory antibodies impact on biochemical and clinical outcomes. Monitoring and tolerisation strategies should be
re-evaluated to improve detection and minimise the inhibitory antibody response to ERT in MPS I and other lysosomal
storage diseases. Future studies should consider the use of sleep disordered breathing as an objective parameter of
clinical and metabolic improvement.
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Mucopolysaccharidosis I (MPS I) is a rare multisystem
lysosomal storage disorder inherited in an autosomal re-
cessive manner with an incidence between 1.07 and 3.8
per 100,000 [1,2]. A deficiency in the enzyme α1- L- iduro-
nidase (IDUA) results in pathological accumulation of the
glycosaminoglycans (GAGs) dermatan sulfate (DS) and
heparan sulfate (HS) [3]. A spectrum of severity in
clinical presentation has been recognized with 50% to
80% of patients classified into a severe phenotype
(MPS I Hurler) with the remainder distributed into at-
tenuated groups (MPS I Hurler-Scheie and Scheie).
Current therapeutic strategies include haematopoietic
stem cell transplantation (HSCT) for the Hurler pheno-
type and enzyme replacement therapy (ERT) in attenu-
ated cases [4,5].
Life threatening involvement of the respiratory system
is a well-recognised feature of MPS. A common manifest-
ation of upper airway disease in MPS I is with sleep dis-
ordered breathing (SDB) and obstructive sleep apnoea
syndrome (OSAS) [6,7]. Sleep disordered breathing de-
scribes a spectrum of symptoms and signs characterized
by an abnormal respiratory and ventilatory pattern dur-
ing sleep, encompassing snoring, upper airways resist-
ance syndrome and OSAS. These occur as a consequence
of increased upper airway resistance due to the multilevel
skeletal, oral, adenotonsillar, laryngeal and tracheal in-
volvement seen in MPS I [8-10]. OSAS is characterized
by recurrent episodes of partial or complete airway ob-
struction during sleep with oxygen desaturations [11].
Multichannel polysomnography is able to measure the
severity of these episodes based on an apnoea-hypopnoea
index, while resultant desaturations may be measured by
overnight transcutaneous oximetry. Failure to recognise,
and treat, moderate to severe SDB has behavioural and
physiological consequences, including failure to thrive,
neurocognitive and developmental delay and, in severe
cases, cardiorespiratory sequellae [12,13].
The existing literature describing the incidence of
OSAS in MPS is based on cross sectional analysis of
small cohorts, primarily performed prior to initiation
of treatment [6,7,14,15]. Short-term longitudinal data is
available from the early Phase III ERT trials, assessing
the role of a single therapeutic intervention on OSAS
[16-18]. We describe sleep oximetry data in the largest
MPS I cohort to date identifying demographic and bio-
chemical factors, including the impact of inhibitory
antibodies, that affect the presence and severity of
sleep disordered breathing following treatment with ei-
ther ERT or HSCT.
Methods
MPS I patients, treated at the Royal Manchester Children’s
Hospital, Manchester, UK and the Academic MedicalCentre, Amsterdam, The Netherlands between 2003–
2013, were identified from existing patient databases. A
study group of 61 patients in whom long-term follow-up
was available at the two centres were included in the
study. Patients were recruited following consent to donate
blood, which is routinely sought from all MPS patients in
Manchester with appropriate ethical approval (REC No.
08/H1010/63, North West Research Ethics Committee;
Central Manchester University Hospital NHS Foundation
Trust Research & Development Committee). The clinical
notes of patients were retrospectively reviewed for over-
night sleep oximetry studies, therapeutic and biochemical
data.
Clinical investigations and biomarker endpoints
The primary endpoint measured was the presence, pro-
gression and severity of sleep disordered breathing (SDB),
based on overnight sleep oximetry data. Secondary end-
points included leukocyte IDUA enzyme activity one year
post HSCT, the urine dermatan sulphate: chondroitin
sulphate (DS:CS) ratio biomarker and requirement for
therapeutic airway intervention following commencement
of treatment for MPS.
Sleep disordered breathing endpoints based on overnight
sleep oximetry
Studies were performed during un-sedated natural sleep,
using sleep oximetry equipment (Pulsox 300i, Konica
Minolta) measuring transcutaneous oxygen saturation
and pulse rate with a finger monitor. Sleep studies were
performed routinely as part of annual assessment guide-
lines, prior to general anaesthesia or if clinically indi-
cated by symptoms [4,19].
The presence and severity of significant SDB was de-
termined by oxygen desaturation index 4% (ODI4%),
percentage of time spent below 90% oxygen saturation
(SpO2) and the median SpO2. Based on guidelines from
the Working Party on Sleep Physiology and Respiratory
Control Disorders in Childhood, Royal College of Paedi-
atrics and Child Health (2009) [20] the criteria of abnor-
mality in nocturnal oximetry recordings are falls of more
than 4% below baseline oxygen saturation and transient
desaturations below 90%. Based on normative data, a
normal oximetry recording should have a median SpO2
level greater than 95% and no more than 4 desaturations
of 4% or greater per hour (ODI4%: 5–10 moderate, >10
severe SDB) [21,22].
Binary endpoints were determined for the presence of
significant SDB (ODI 4% > 5 events per hour and
median saturation <95%) and for progression (deterior-
ation in ODI4% of greater than 1 event/hour, and 1% or
greater drop in median SpO2 in studies more than 1 year
apart). Studies performed in patients following a
therapeutic surgical airway intervention, such as
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ous positive airways pressure (CPAP), while on treat-
ment for MPS were excluded from the analysis and are
indicated in Figure 1.
Urinary glycosaminoglycan and enzyme assay for
α-L-iduronidase activity
Measurement of DS:CS ratio biomarker was performed by
the Willink Biochemical Genetics Laboratory, St. Mary’s
Hospital, Manchester, UK as part of routine clinical mon-
itoring of disease progression from urine, by two-
dimensional electrophoresis on cellulose-acetate sheets
[23]. GAGs were separated into discrete spots and lo-
cated after staining with Alcian blue and washing with
5% Acetic Acid. Semi-quantitative measurement of the
area of two-dimensional electrophoresis spots of extracted
GAG were made under white light using the UVP Gel
Photography system and LabWorks software (Anachem,
Luton, UK) [24,25]. This biomarker provides a measure of
the degree of pathological GAG substrate accumulation in
comparison to non-pathologically stored chondroitin
sulphate.
The activity of α-L-iduronidase (IDUA) was measured
on leucocytes isolated from peripheral blood based on
catabolism of the artificial fluorescent substrate 4-
methylumbelliferyl-α-L-iduronide (Glycosynth, Warrington,
UK) as described previously [26]. Enzyme activity was
expressed as μmol/g total protein/hour (normal reference
range 10–50, heterozygote range 5–25).
Antibody detection and cellular uptake inhibition assay
Patient serum antibody titres towards ERT and cellular
uptake inhibition were measured using two assays as de-
scribed previously [27]. Briefly, the antibody detection
assay used an immunoglobulin G enzyme linked immuno-
sorbent assay (ELISA) to detect and quantify patient
serum antibodies against recombinant IDUA enzyme
(Aldurazyme, Genzyme, Framingham, USA, 10 μg/ml).
Antibody titre for each patient sample was based on two-
fold serial dilutions of serum starting from a 1:8 to a
1:262,144 dilution. Control serum, from patients without
MPS, was used to define a baseline. The cut off values for
antibody titre for the ELISA were determined using the
following formula for each dilution.
Cut off value ¼ Mean absorbance of patient sample – 1SD½ 
– Mean absorbance of normal serumþ 2SD½ 
A value above zero indicates a positive result. The titre
above the last negative value (last positive dilution) is re-
ported as the positive titre for that patient sample. The
cellular uptake inhibition assay quantifies the level of
catalytically active recombinant enzyme taken up into
cultured enzyme naive MPS I patient fibroblasts. The
ability of enzyme to catalyse a fluorescent artificialsubstrate (4MU-α-L-iduronide) is measured. Cellular
uptake of enzyme proceeds via the Mannose-6-Phosphate
(M-6-P) ligand receptor uptake pathway. Rather than test-
ing only for inhibition of catalytic activity, neutralisation
of enzyme uptake via the M-6-P pathway is also assessed.
Cultured cells are incubated with enzyme and antibodies
from patient sera. Prior to assessing fluorescence, extracel-
lular enzyme that has not been successfully internalised is
washed. Therefore, following cell lysis the substrate assay
only quantified intracellular enzyme. The protein content
of each assay well was corrected for using the Pierce
Bicinchoninic acid (BCA) assay (Thermoscientific) ac-
cording to the manufacturer’s instructions.
The % inhibition of the catalytic activity was measured
as follows:
% Inhibition ¼ 100−100 
Enzyme activity of lysate incubated
with patient serum
Enzyme activity of lysate incubated
with normal serum control
Statistical analysis
Descriptive statistics were calculated for demographics,
sleep oximetry and biochemical data. Significant associa-
tions between patient, biomarker and treatment-related
variables and primary endpoints for all patients, HSCT
treated Hurler and ERT treated attenuated subgroups
were identified using multivariate stepwise regression
modelling using the minimum corrected Akaike infor-
mation criterion (AICc), followed by logistic regression
for binomial outcomes and standard least squares for
continuous outcomes. The relationship between these
variables is individually presented. For continuous out-
comes, to ensure equal weighting, the mean value for
sleep oximetry data and timepoints were calculated. Sig-
nificance was assumed where 95% confidence intervals
did not include 1 (p-values <0.05). Possible confounding
variables including age at start of treatment and duration
of follow-up were included in the model. JMP v11.0 soft-
ware (SAS) was used for this analysis. For correlation
plots, linear regression lines of best fit were drawn and
correlation coefficients were calculated with Pearson’s r
and Spearman’s rho for normally and non-normally dis-
tributed data sets respectively. T-test and Mann–Whitney
tests were used to identify differences between the base-
line characteristics of subgroups.
Results
Study demographics
Clinical data for 61 patients, with a median age of 6.8 years
at the time of final assessment, were collected (median
duration of follow-up 22 months, range 1–60 months).
Forty-four patients were classified as severe Hurler based
on genotype and enzyme studies at diagnosis (median age
at follow-up 4.7 years, range 10 months – 16 years,
A. HSCT Treated Hurler patients
B. ERT Treated patients
Figure 1 Longitudinal trends in sleep disordered breathing (SDB) following treatment in MPS I patients treated with A. haematopoietic
stem cell transplant (HSCT) or B. enzyme replacement therapy (ERT). Oxygen desaturation index 4% (ODI4%) data from sleep studies for
each individual patient is plotted against duration since initiation of treatment, with solid lines connecting trends per patient. The shaded area
represents an ODI4% of less than 10, representing the cut-off for severe SDB. Red legend identifies patients who require therapeutic intervention
to the airway following the identified sleep study. (A). Data for 41 patients is presented. Hurler patients (circles) treated with HSCT show improvement
in the severity of SDB compared to pre-treatment. Over the duration of follow up the majority of patients (76%) improve or remain stable. A reducing
proportion of patients suffer severe SDB, with only one patient demonstrating severe SDB in the period after 3 years post HSCT. 3 patients require
therapeutic intervention post-HSCT. (B). Data in 17 ERT treated attenuated patients (triangles) and 3 Hurler patients (circles) is presented. Amongst
attenuated patients with longitudinal data, 73% are seen to progress, but rarely to severe SDB However, a cohort of attenuated patients developing
inhibitory antibodies (open triangles) continue to suffer with severe SDB. 7 patients require therapeutic intervention (surgery or CPAP) while on ERT.
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nosed as the attenuated phenotype (median 9.7 years,
range 5.2-35 years, median follow-up duration 595 days).
Forty-one of 44 Hurler were treated with HSCT with a
median age at transplantation of 14 months old, while 3Hurler patients were treated with ERT alone due to de-
layed diagnosis and advanced disease at initiation of
treatment (mean 8.4 years, range 6.2-12 years). All 17 at-
tenuated patients were treated with ERT, with a median
age at start of treatment of 60 months. Subject
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in Table 1.
Primary endpoint: sleep disordered breathing
Based on analysis of parameters from 127 post-treatment
sleep oximetry studies, significant SDB was present in 68%
(36/53, ODI4% > 5/hr) of our cohort. Table 2 summarises
the descriptive statistics for sleep oximetry results includ-
ing for phenotype and therapy subgroups.Table 1 Baseline patient and treatment characteristics
Patient characteristics: N %
All MPS I 61
Gender (male/female) 38/23 62/38
Phenotype (Hurler/Attenuated) 44/17 69/31
Age @ Start of treatment (mths)
Age @ final assessment (mths)
HSCT treated Hurler patient characteristics
Gender (male/female) 30/14
Age @ Start of treatment (mths)
Age @ final assessment (mths)
Interventions
Therapeutic airway intervention post-HSCT 3 7%
Treatments and metabolic characteristics
No HSCT (1/2/3) 32/8/1 78/20/2
Source (CB/BM/PBSC/Unknown) 17/15/7/2 41/37/1
Donor (Related/MUD) 15/26 37/63
IDUA @ 1 year post HSCT 36
Heterozygote Donors 12
Matched Unrelated Donors 24
Pre HSCT DS:CS ratio 20
DS:CS ratio @ 1 year 32
ERT treated Hurler Patients
Gender (male/female) 2/1
Age @ Start of treatment (mths)
Age @ final assessment (mths)
ERT Treated attenuated patients
Gender (male/female) 9/8
Age @ Start of treatment (mths)
Age @ final assessment (mths)
Interventions
Therapeutic airway intervention on ERT 7 41%
Metabolic characteristics
Pre ERT DS:CS ratio 5
DS:CS ratio @ 1 year 13
All characteristics concern the last HSCT. BM indicates bone marrow; CB, cord blood; ID
donor; N, number; PBSC, peripheral blood stem cells.Amongst post-transplant Hurler patients, SDB was
present (ODI > 5%) in 69% but seen to progress in only
24%. In those with both pre and post HSCT studies (n = 8)
a significant improvement in the severity of SDB was seen
after treatment (median ODI4%; pre HSCT: 9.5/hr vs. post
HSCT 4.1/hr; p = 0.02). Longitudinal analysis of HSCT
treated Hurler patients demonstrate that 13% (4/30) pa-
tients had evidence of severe OSA (ODI4% > 10) after as-

















Adenotonsillar Surgery: 2 pts (1 had revision)
1.9 1.1-2.7
0.8 0.4-2.2
UA, alpha-L-iduronidase enzyme level; mths, months; MUD, matched unrelated
Table 2 Sleep oximetry characteristics
All patients N % Missing Median Range
No of Studies 150 2 per pt 1.0-9.0
Duration since treatment start (years) 3.3 0.1-15.7
Duration of final assessment since treatment start (years) 8 pts pre-treatment studies only 4.4 0.1-15.7
Patients with sleep disordered breathing (present/absent) 36/17 68/32 8 (SDB present in 6/8 with only pre-treatment studies)
Progression of sleep disordered breathing (yes/no) 15/22 41/59 24
ODI 4% Post treatment 6.1 0.1-46.0
Median oxygen saturation Post treatment 95.4 83.9-98.1
% Time < 90% Oxygen saturation Post treatment 2.2 0.0-30.8
HSCT treated Hurler patient
No of Studies 106
Time post treatment start (years) 3.1 0.1-14.9
Sleep disordered breathing post HSCT present/absent 24/11 69/31 6
Progression of SDB in patients with multiple studies yes/no 6/19 24/76 16
No of pre-treatment studies 19 In 14 patients
Pre-treatment ODI 4% 9.5 1.3-39.9
Pre-treatment Median oxygen saturation 96.2 81.6-98.5
Pre-treatment % Time < 90% Oxygen saturation 4.1 0-14.2
No. of post treatment studies 87 In 35 patients
ODI 4% Post treatment 5.8 0.2-19.8
Median oxygen saturation Post treatment 95.4 87.4-99.6
% Time < 90% Oxygen saturation Post treatment 1.75 0-30.8
ERT treated Attenuated Patients
No of Studies 44
Time post treatment start (years) 3.5 0.7-8.0
Sleep disordered breathing (SDB) present 11/6 65/35
Progression of SDB yes/no 8/3 73/27 7
No of pre-treatment studies 4 In 3 patients
Pre-treatment ODI 4% 5.7 0.2-14.8
No of post treatment studies 40 In 17 patients
ODI 4% Post treatment 6.9 0.1-46
Median oxygen saturation Post treatment 95.1 83.9-98.1
% Time < 90% Oxygen saturation Post treatment 3.2 0-17.25
N indicates number; SDB, Sleep disordered breathing.
ODI 4%, oxygen desaturation index 4%.
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up of greater than 3 years post HSCT (Figure 1A).
Following ERT initiation in attenuated patients, SDB
was deemed to be present in 65% (ODI > 5%), but seen
to progress in 73% (Figure 1B; ERT vs. HSCT, p = 0.013).
Thirty-six percent (5/14) of those with follow up over
1 year have severe SDB and this increased to 45% (5/11)
with studies after 3 years of ERT.
Airway interventions
Sixteen percent (10/61) of the study population required
13 episodes of therapeutic airway intervention followinginitiation of ERT/HSCT (Table 1), with a later age at
start of treatment found to significantly correlate with
the need for intervention (p = 0.012). The proportion of
attenuated patients treated with ERT necessitating inter-
vention was 41% (7/17). All patients requiring CPAP
were from the ERT treated attenuated subgroup (n = 5),
while 2 necessitated airway surgery alone. The propor-
tion of HSCT treated Hurler patients undergoing inter-
vention post HSCT was significantly lower at 7% (3/41;
ERT vs. HSCT, p = 0.01) composed of one patient requir-
ing long term oxygen therapy and 2 managed with
adenotonsillectomy.
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breathing
Correlator variables for the outcomes of presence, pro-
gression and severity of long term SDB, as measured by
sleep oximetry were determined following multivariate
analysis (Table 3). Potential confounders, including age
at commencement of treatment and duration of follow-
up were included in the analysis.
DS:CS ratio and metabolic correction
DS: CS ratio was available in 24 patients prior to treat-
ment and post-ERT/HSCT in 47. No significant differ-
ence was present between pre-treatment attenuated and
severe patients (median DS:CS; 1.9 vs 1.6, p = 0.59), while
paired data demonstrated a significant improvement in
post-therapy levels following both ERT (median pre
and post ERT DS:CS; 1.9 vs. 0.6, n = 5, p = 0.02) and
HSCT (median pre and post HSCT DS:CS; 1.6 vs 0.4,
n = 19, p < 0.0001).Table 3 Correlators of sleep related clinical outcome based o
Outcome Modifier Patient group
SDB Present Phenotype All (n = 61)
Treatment
Age @ start of treatment
Follow-up duration
DS:CS ratio @ 1 year
Mean ODI 4% Phenotype All (n = 61)
Treatment
Age @ start of treatment
Follow-up duration
DS:CS ratio @ 1 year
Therapeutic Intervention Phenotype All (n = 61)
Treatment
Age @ start of treatment
Follow-up duration
DS:CS ratio @ 1 year
SDB Present Donor Type HSCT Treated Hurl
IDUA level @ 1 year
Age @ start of treatment
Follow-up duration
DS:CS ratio @ 1 year
ODI 4% at time of
antibody status
DS:CS Ratio ERT Treated Atten
Inhibitory Antibodies
Age @ start of treatment
Follow-up duration
p-values for modifiers based on multivariate analysis using stepwise fit (minimum A
fit for binomial outcomes. CI indicates confidence interval; ERT, enzyme replacemen
enzyme level; SDB, Sleep disordered breathing; ODI 4%, oxygen desaturation index 4%Metabolic correction, measured by a fall in the bio-
marker DS:CS ratio, correlates significantly with clinical
regression of airway disease following treatment, as mea-
sured by ODI4% at an identical time point (oximetry
within 4 weeks of urine sample) (Figure 2A (p < 0.0001)).
This association continues to be significant amongst the
entire cohort in the multivariate analysis, correcting for
age at start of treatment and at assessment, for the pres-
ence of SDB (Figure 2B; Table 3: DS:CS @ 1 year and
presence (multivariate p = 0.0017) and severity of SDB
(p = 0.008)).
IDUA enzyme activity post-HSCT
Engrafted leukocyte IDUA enzyme activity was docu-
mented at one-year post transplant (Table 1). Stratified
by donor type, patients receiving HSCT demonstrated
greater enzyme activity (Table 1; median IDUA, hetero-
zygote: 19.7 vs unrelated 34.6, p = 0.01) and greater sub-
strate clearance (median DS:CS ratio; heterozygote 0.40n multivariate analysis
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Figure 2 Metabolic biomarkers of clinical outcome in MPS I. Substrate reduction, measured by DS:CS ratio, and delivered enzyme activity
following HSCT correlate significantly with measures of sleep disordered breathing (SDB) amongst MPS I patients. Bars represent means with p
values presented from Mann–Whitney U (Multivariate p values are presented in Table 3). For correlation plots, linear regression lines of best fit
were drawn and correlation coefficients were calculated with Pearson’s r, with p values representing significantly non-zero lines of best fit. Hurler
patients identified by circle legend and attenuated by triangles. Each individual point represents one patient. (A). The ODI4% from the first post
treatment sleep study of each patient correlates strongly to urinary DS: CS ratio performed at an identical time point (sleep study and urine
sample collected within 4 weeks). Pearson Correlation r = 0.79 (r2 = 0.68), p < 0.0001. (B). Mean urinary DS:CS ratio 1 year after treatment was
significantly improved in individuals without SDB (mean 0.47, S.D 0.15), compared to those with SDB (mean 0.75, S.D 0.48, p = 0.04). Amongst ERT
treated patients, patients with inhibitors drive worsening SDB. (C). Increasing iduronidase (IDUA) one year following transplant correlates
significantly with improved DS:CS ratio at one year (r = −0.70, p < 0.001). (D). Iduronidase enzyme activity one year post transplant is significantly
higher when SDB was absent (mean 44.69, S.D 20.8), compared to those where SDB was present (mean 29.33, S.D 12.9, p = 0.011). HSCT, Matched
unrelated donor (MUD): closed circles. HSCT, Heterozygote donors: open circles. Attenuated patients on ERT without antibody response: closed
triangles: Attenuated ERT patients with inhibitors: open triangles.
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unrelated donors with two copies of the missing IDUA
gene as opposed to heterozygote, related donors express-
ing one gene copy. Greater enzyme levels were seen to
confer greater substrate clearance (Figure 2C, p < 0.001).
IDUA enzyme level at one year post HSCT correlated
significantly for the presence of SDB, correcting for age
at HSCT and at assessment (p = 0.011, Figure 2D).Immune response to ERT
The results from the antibody detection and cellular up-
take inhibition assay are described in Table 4. Increasing
inhibition of enzyme activity by antibodies correlated
significantly with poorer substrate reduction (DS:CS ra-
tio) in ERT patients, Figure 3A (p = 0.0002). Inhibitory
antibodies were deemed effectual in patients with both a
raised IgG antibody titre above 1/4000 dilution and
Table 4 ERT related immune response








1 Hurler 11 13* 262336 86.1 Yes*
2 Hurler 7 7 65536 41.8 No
3 Hurler 6 7 262144 88.3 Yes
4 Hurler-Scheie 5 7* 262336 0 No
5 Hurler-Scheie 4 4* 32768 33.0 Yes*
6 Hurler-Scheie 5 13* 32768 95.4 Yes*
7 Hurler-Scheie 8 15 256 0 No
8 Hurler-Scheie 6 13* 512 0 No
9 Hurler-Scheie 3 9* 1 n/a No
10 Hurler-Scheie 3 10* 256 0 No
11 Hurler-Scheie 7 14* 1 n/a No
12 Hurler-Scheie 12 12 4096 0 No
13 Hurler-Scheie 2 7* 1 n/a No
14 Hurler-Scheie 4 4 32768 25.5 No
15 Hurler-Scheie 4 7* 256 30.09 No
16 Hurler-Scheie 4 7* 32 1 No
17 Scheie 30 30 131072 58.10 No
18 Scheie 27 28* 262144 30.12 Yes*
19 Scheie 15 15 4096 11.6 No
20 Scheie 9 10* 2048 31.4 No
*Sleep study and biochemical data available within 6 months of determination of antibody status.
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on extrapolation from the upper CI at baseline and its
intersection of the lower CI; Figure 3A).
Eleven (52%) individuals were identified as having IgG
antibody titres greater than 4000. Of these, 7 (33%) dem-
onstrated uptake inhibition above 30%. All Hurler pa-
tients treated with long term ERT (not treated with
HSCT, n = 3) in this cohort demonstrated a strong in-
hibitory antibody response. Patients with titres above
4000, and uptake inhibition above 30% had significantly
worse DS:CS ratios (performed within 6 months) than
those without inhibitory antibodies, Figure 3B; p = 0.003.
Notably, ERT corrected patients without inhibitors had
similar DS:CS ratios to Hurler patients receiving HSCT
(Figure 3B).
Of the 4 attenuated patients, 3 demonstrated both
high titres and uptake inhibition over 1 year after ERT
had started and had SDB and biochemical data available
within 6 months of antibody status determination (Iden-
tified with asterisk, Table 4). These 3 patients began ERT
aged 4.5 years, 5.9 years and 26.9 years respectively. All
demonstrated evidence of severe SDB (ODI > 10%) on
assessment, and have required therapeutic intervention
while on ERT (CPAP in 2, Surgery in 1; Figure 1B). Pa-
tients with significant levels of inhibitory antibodies all
showed significantly elevated SDB over ERT treatedpatients without inhibitory antibodies, as confirmed by
multivariate analysis (Table 4; Figure 3C; open triangle
legend).
Discussion
This is the first paper to present long-term post-
treatment outcomes for airway obstruction in MPS I and
to correlate objective parameters of clinical airway dis-
ease with both metabolic correction and levels of inhibi-
tory antibodies. We see more advanced clinical airway
disease in patients with poorer substrate clearance, indi-
cated by raised DS:CS ratio. Hence, factors optimising
substrate reduction and engrafted delivered enzyme in
HSCT, primarily non-carrier donor selection and full
donor chimerism [24,25], will have a beneficial effect on
respiratory outcome; whereas, amongst ERT treated in-
dividuals, factors compromising metabolic clearance
such as inhibitory antibodies to ERT and delayed treat-
ment impair clinical outcome.
These results endorse the ability of sleep oximetry to
discriminate patients based on severity of metabolic dis-
ease and subsequent correction following treatment, and
suggest oximetry could serve as quantitative and clinic-
ally relevant primary outcome parameter representative
of clearance of GAGs and derived polysaccharides re-
sponsible for obstructive airway disease. Recent studies
AB C
Figure 3 The role of inhibitory antibodies on metabolic biomarker and sleep disordered breathing (SDB) amongst ERT treated MPS I
patients. Bars represent means with p values presented. For correlation plots, linear regression lines of best fit were drawn and correlation
coefficients were calculated with Pearson’s r, with p values representing significantly non-zero lines of best fit. HSCT treated Hurler patients: closed
circles. Hurler patients treated with ERT: Half shaded triangles. ERT patients with clinically significant inhibitory antibodies were defined as a
cellular uptake inhibition greater than 30% & titres greater than 4000 (Open triangles). ERT treated patients without such an antibody response
represented by closed triangles. (A). Correlation plot with linear regression lines of best fit for cellular uptake inhibition and DS:CS ratio. Increasing
activity of inhibitory antibodies correlates strongly with poorer substrate clearance (urinary DS:CS ratio performed within 6 months of antibody
status) (r2 = 0.74, p = 0.002). 30% uptake inhibition is a suggested percentage with a measurable biochemical effect based on intersection of
upper confidence intervals at baseline and lower CI. (B). Urinary DS:CS ratio within 6 months of antibody status was significantly improved in
individuals without inhibitory antibodies (mean 0.61, S.D 0.14) compared to those with inhibitors (mean 1.8, S.D 0.76). As a reference, ERT attenuated
patients without inhibitors have as successful metabolic outcomes as HSCT treated Hurler patients (mean 0.47). (C). SDB as measured by ODI4% within
6 months of antibody status was significantly lower in individuals without inhibitory antibodies (mean 2.03, S.D 1.68) compared to those with inhibitors
(mean 16.85, S.D 7.23).
Pal et al. Orphanet Journal of Rare Diseases  (2015) 10:42 Page 10 of 13have qualitatively confirmed the utility of signs of upper
airway obstruction as a means to differentiate between
severe and attenuated phenotypes in MPS [28]. Further-
more, the clear relationship between metabolic correc-
tion, delivered enzyme and clinical outcome suggests
that in the future, autologous stem cell gene therapy, asa means to maximise disease correction based on supra-
normal enzyme levels [29,30], may further minimise the
continuing burden of disease in this population.
From our analysis of long term outcome, HSCT ap-
pears to provide sustained metabolic correction and sub-
sequent reduction in airway obstruction, with only a
Pal et al. Orphanet Journal of Rare Diseases  (2015) 10:42 Page 11 of 13small proportion suffering with progressive or severe
SDB after 3 years post-transplant. In contrast, a greater
proportion of ERT managed attenuated patients are seen
to progress, require therapeutic intervention and suffer
severe SDB. These findings strengthen the description of
other studies that fewer airway related complications are
seen following successful HSCT than ERT [31]. How-
ever, it must be borne in mind that a formal comparison
of clinical outcomes between HSCT and ERT treated
groups is necessarily limited in a retrospective study
such as this, due to the heterogeneous nature of un-
treated disease, inequalities in time of assessment and
variation in age at onset of symptoms and disease sever-
ity at start of treatment. Prospective evaluation would
also be hampered by the variation in age at presentation.
One conclusion that may be drawn from our results is
that attenuated patients, receiving their first ERT on
average 46 months after Hurler patients receive HSCT,
are more refractory to treatment as they are older, with
more established clinical disease at initiation of treat-
ment. This includes an older cohort diagnosed prior to
the era of ERT. Whilst acknowledging the significance of
age at start of treatment and follow-up duration in af-
fecting clinical outcome, our multivariate analysis dem-
onstrated DS:CS ratio and inhibitory antibodies to still
be significant correlators of SDB taking into account the
above confounders.
Further analysis amongst ERT patients, identifies two
groups of patients. Almost all of the worsening meta-
bolic (Figure 3B) and SDB effects (Figure 3C), are medi-
ated by a small cohort of ‘non-responders’ with clinically
meaningful, high levels of inhibitory antibodies; while
the majority, without such a response, demonstrate ex-
cellent biochemical and clinical improvement. Allowing
for low patient numbers and variation in time points,
this effect continues to prove significant following ana-
lysis accounting for age at start of treatment and at
follow-up. This suggests that both HSCT and ERT would
be equally effective at reducing metabolic and airway
obstruction if inhibitory antibodies could be eliminated
in ERT.
Although recombinant protein replacement therapies
in several diseases, particularly Pompe and to a lesser
extent haemophilia, have been shown to have a negative
clinical response to inhibitory antibody induction [32],
this has not been the case in MPS I. 91% of MPS I pa-
tients treated with laronidase on the original ERT trial
developed IgG or IgM allo-antibodies to recombinant
enzyme [16], although no evidence of poor clinical out-
come has been demonstrated in MPS until now. The
cellular uptake assay to measure inhibitory antibodies,
used in conjunction with stratification into subsets with
high IgG titres is required to truly evaluate the impact
of such antibodies and provides a more meaningfulreflection of in vivo processes required for effective sub-
strate clearance with ERT compared to an in vitro en-
zyme catalytic inhibition assay alone [27]. This has
recently been clearly correlated with several metabolic
biomarkers, including DS:CS ratio [33]. The strong cor-
relation seen between DS:CS ratio and ODI4% reasserts
our findings that an allo-immune response that impairs
substrate clearance is likely to reduce the clinical
efficacy of ERT in MPS and merits further prospective
collaborative investigation using a standardized assay
in a larger cohort. Thus presence of greater than 30%
cellular inhibition, whilst removing patients with
clinically ineffectual low IgG titres, delineates between
patients with worse SDB from those with improved SDB
(Figure 3C).
We acknowledge the limitations of our study, includ-
ing cohort size, especially amongst the ERT group, and
retrospective nature of data collection. Full multichannel
polysomnography was not available in a significant pro-
portion of patients, as a result, formal quantification of
OSA based on apnoea-hypopnoea index (AHI) was not
possible; however, correlation between AHI and ODI in
patients undergoing both studies was good and therefore
sleep oximetry data was used. Non-invasive oximetry is
well tolerated, and we were able to perform studies in al-
most all patients including those with advanced disease.
Data on the use of sleep oximetry for the identification
of OSA have suggested that when positive, the results
show good correlation with PSG, but a potentially poor
predictive value if results were negative [21] [34]. This
potential error was minimised given the high incidence
of SDB in our cohort and as the majority of patients
underwent multiple studies.
Conclusion
As a chronic disease with poorly defined global clinical
outcomes, being able to demonstrate a clear correlation
between clinical airway obstruction and metabolic cor-
rection is a significant finding. The findings of this study
have a number of potential implications for the current
management of SDB in MPS I. Firstly, optimising meta-
bolic correction, monitored by biomarker response, can
be seen to improve respiratory outcome. We also iden-
tify that HSCT in Hurler patients and ERT in attenuated
individuals without inhibitory antibodies results in sus-
tained correction of airway disease. However, a cohort of at-
tenuated patients demonstrates advanced disease, which
appears to be driven by raising inhibitory antibody
responses. The correlation between worsening substrate re-
duction and SDB to inhibitory antibodies requires further
investigation and suggests that monitoring of inhibitory
antibodies and investigation of tolerisation regimens
to prevent such a response is needed to form part of
routine management of ERT treated patients in future.
Pal et al. Orphanet Journal of Rare Diseases  (2015) 10:42 Page 12 of 13Alternatively, as the management of risk in HSCT
improves, it may become feasible as a single treatment
modality for both severe and significantly affected
attenuated phenotypes of MPS I.
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